Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 13:14:1170127.
doi: 10.3389/fendo.2023.1170127. eCollection 2023.

Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study

Yilong Yan  1   2 , Ying Gong  3 , Meizhu Jiang  1   2 , Yiming Gao  1   2 , Shanshan Guo  1 , Jiping Huo  1 , Zhigang Zhao  1 , Cao Li  1
Affiliations

Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study

Yilong Yan et al. Front Endocrinol (Lausanne). .

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been widely used in treating type 2 diabetes mellitus (T2DM) and obesity in adults, but scientific research about the indication in children and adolescents is scarce. The current study aims to explore the prescriptions of GLP-1RAs in children and adolescents in China and to evaluate its rationality.

Methods: GLP-1RA prescriptions of children and adolescents were retrospectively obtained from the Hospital Prescription Analysis Cooperative Project. The study extracted information on patient's demographic characteristics, monotherapy and combination therapy of GLP-1RAs, and trends in GLP-1RA usage from 2016 to 2021. The rationality of GLP-1RA prescriptions was comprehensively assessed based on the indications approved by China National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), and published randomized controlled trials (RCTs).

Results: A total of 234 prescriptions from 46 hospitals were included, with a median age of 17 years old. The majority of patients were diagnosed with overweight/obesity or prediabetes/diabetes, accounting for 43.59% and 46.15%, respectively. There were 88 patients on GLP-1RA monotherapy. GLP-1RAs plus metformin was the most common combination therapy (38.89%). 12.39% of patients were found a co-administration with orlistat. The share of overweight/obesity prescriptions increased from 27% in 2016 to 54% in 2021, whereas prediabetes/diabetes prescriptions declined from 55% to 42%. The prescriptions were divided into appropriate and questionable groups according to the diagnosis, and the potentially questionable prescription was related to age (p = 0.017), department visited (p = 0.002), and any hospitalization (p < 0.001).

Conclusions: This study described the prescribing of GLP-1RAs in children and adolescents. Our findings indicated that the utilization of GLP-1RAs has increased from 2016 to 2021. There was a strong basis for administering GLP-1RAs in overweight/obesity and prediabetes/diabetes, whereas the evidence was insufficient in other conditions. It is crucial to demand robust and sustained efforts to enhance the awareness of the safety of utilization of GLP-1RAs in children and adolescents.

Keywords: GLP-1RA; adolescents; children; diabetes; obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram for study cohort inclusion.
Figure 2
Figure 2
Trends in the use of GLP-1RAs in obese and diabetic patients.
See this image and copyright information in PMC

References

    1. Guidelines for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Pract Internal Med (2021) 41(08):668–95. doi: 10.19538/j.nk2021080106 - DOI
    1. Brown E, Cuthbertson DJ, Wilding JP. Newer GLP-1 receptor agonists and obesity-diabetes. Peptides (2018) 100:61–7. doi: 10.1016/j.peptides.2017.12.009 - DOI - PubMed
    1. Salam RA, Padhani ZA, Das JK, Shaikh AY, Hoodbhoy Z, Jeelani SM, et al. . Effects of lifestyle modification interventions to prevent and manage child and adolescent obesity: a systematic review and meta-analysis. Nutrients (2020) 12(8):2208. doi: 10.3390/nu12082208 - DOI - PMC - PubMed
    1. Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol (2021) 9(6):373–92. doi: 10.1016/S2213-8587(21)00045-0 - DOI - PubMed
    1. Chen X, Pei Z, Zhang M, Xu Z, Zhao Z, Lu W, et al. . Glycated hemoglobin (HbA1c) concentrations among children and adolescents with diabetes in middle- and low-income countries, 2010-2019: a retrospective chart review and systematic review of literature. Front Endocrinol (2021) 12:651589. doi: 10.3389/fendo.2021.651589 - DOI - PMC - PubMed

Publication types

Substances